Drug Review

FDA Approves Vyzulta (latanoprostene bunod) Ophthalmic Solution for Open-Angle Glaucoma, Ocular Hypertension

Following topical administration, Vyzulta, a once daily monotherapy with a dual mechanism of action, works by metabolizing into two moieties, latanoprost acid, which primarily works within the uveoscleral pathway to increase aqueous humor outflow, and butanediol mononitrate, which releases NO to increase outflow through the trabecular meshwork and Schlemm's canal. The most common ocular adverse events include conjunctival hyperemia, eye irritation,

Read more
Ivabradine – the first selective sinus node If channel inhibitor in the treatment of chronic stable angina with normal sinus rhythm.

Ivabradine is currently the only agent shown to clinically lower heart rate with no negative inotropism or effects on conduction and contractility. Lowering heart rate is therefore one of the most important therapeutic approaches in the treatment of stable angina pectoris, which reduces myocardial oxygen demand, simultaneously improving oxygen supply. Mechanism of action: Ivabradine acts on the If  ion current, which is highly expressed in the SA

Read more